Shares of Antigenics ( AGEN) were among the best-performing health-related stocks Monday, rising 13% after the biotechnology company posted preliminary data from its phase III trial showing that Oncophage improved the survival rate in patients with metastatic melanoma by about eight months.

The drug improved median survival by more than 50% compared to patients who were subjected to a physician's treatment choice, which included therapies such as chemotherapeutics, biologic agents or surgery. While the treatment improved survival compared to other treatments, the company cautioned that the difference "has not achieved statistical significance at the time of this preliminary analysis." A final analysis is expected during the first quarter of 2006. Shares were trading up 63 cents to $5.64.

Universal Health Services ( UHS) rose 2% after the company agreed to acquire Keys Group Holdings for $207 million in cash. The acquisition is expected to add about $165 million in annual sales to Universal's results. The operational effective date, said Universal, is Oct. 1, 2005.

Universal Health also said that its board authorized an additional 2 million shares for repurchase, which will supplement the company's other buyback plan. Under the company's previous repurchase plan, the company still has 2.1 million shares remaining. The company was also granted authorization to buy its convertible debentures due 2020. Shares were trading up 76 cents to $46.94.

Shares of Micro Therapeutics ( MTIX) rose 19% after its largest shareholder, ev3 ( EVVV), offered to buy the remaining 30% of the company that it doesn't already own. Ev3 would issue about 6.6 million shares to the company, representing a purchase price of about $7.90 a share, based on Friday's closing prices. The deal represents a 33% premium. "The combination of the two companies will facilitate the realization of efficiencies in sales and marketing as well as research and development," ev3's chief executive said in a statement. "In addition, the transaction will result in significant cost savings as redundant public company and other general and administrative expenses are eliminated." Shares of Micro Therapeutics were trading up $1.10 to $7.04, while shares of ev3 were trading down $1.34 to $15.91.

If you liked this article you might like

Thursday's Tech Winners & Losers

Thursday's Tech Winners & Losers

Thursday's Winners & Losers: FTD

Thursday's Winners & Losers: FTD

Wednesday's Winners & Losers: Superior Offshore

Wednesday's Winners & Losers: Superior Offshore

Wednesday's Tech Winners & Losers

Wednesday's Tech Winners & Losers

Tuesday's Winners & Losers: Fossil

Tuesday's Winners & Losers: Fossil